SCHEMBL5582247

SCHEMBL5582247

CNc1ncc2c(-c3cccc(Cl)c3)cc(-c3ccccc3O)c(OC)c2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 8/20 0.39
FYN P06241 1/20 0.38
CSNK2A2 P19784 1/20 0.37
CSNK2B P67870 1/20 0.37
CSNK2A1 P68400 1/20 0.37
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
NR1I3 Q14994 1/20 0.34
MAP4K4 O95819 1/20 0.34
TUBB4A P04350 1/20 0.34
TUBB P07437 1/20 0.34
TUBA3C P0DPH7 1/20 0.34
TUBA1B P68363 1/20 0.34
TUBA4A P68366 1/20 0.34
TUBB4B P68371 1/20 0.34
TUBB3 Q13509 1/20 0.34
TUBB2A Q13885 1/20 0.34
TUBB8 Q3ZCM7 1/20 0.34
TUBA3E Q6PEY2 1/20 0.34
TUBA1A Q71U36 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5581820 0.89 ADORA1 (0.43) ADORA1CSNK2A2CSNK2BCSNK2A1JAK2
SCHEMBL5581799 0.89 FYN (0.41) ADORA1FYNCSNK2A2CSNK2BCSNK2A1
SCHEMBL5582071 0.88 FYN (0.39) ADORA1FYNCSNK2A2CSNK2BCSNK2A1
SCHEMBL5582093 0.87 CSNK2A1 (0.49) ADORA1CSNK2A2CSNK2BCSNK2A1MAP4K4
SCHEMBL5581770 0.87 ADORA1 (0.40) ADORA1FYNCSNK2A2CSNK2BCSNK2A1
SCHEMBL5581729 0.87 FYN (0.52) FYNJAK2JAK1MEN1KMT2A
SCHEMBL5582299 0.85 CSNK2A2 (0.37) ADORA1FYNCSNK2A2CSNK2BCSNK2A1
SCHEMBL5581976 0.83 PDE4B (0.39) ADORA1FYNCSNK2A2CSNK2BCSNK2A1
SCHEMBL5581995 0.83 CSNK2A1 (0.50) ADORA1CSNK2A2CSNK2BCSNK2A1MAP4K4
SCHEMBL5582028 0.83 SCN9A (0.40) ADORA1FYNCSNK2A2CSNK2BCSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225308-A1 2-Amino Quinazoline Derivative KYOWA HAKKO KOGYO CO.,LTD. (JP) 2007-09-27 US disclosed
EP-1726584-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225308-A1 2-Amino Quinazoline Derivative AGTR2, ABL1, AGTR1 ADORA1 406/4885FYN 2211/4885CSNK2A2 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.